Abstract
Background & Aim: In allogeneic hematopoietic cell transplantation (HCT), NMDP guidelines are for stem cell product (SCP) infusion within 48 hrs or as soon as feasible after collection. However, given the possibility of long transit times, staffing limitations, and travel disruptions from natural disasters or pandemics, delays occur in the timing of infusions. We performed a pilot study to evaluate the safety of delayed SCP infusions. Methods, Results & Conclusion: We prospectively determined total transit time (time from end of collection to end of HCT infusion, TTT), viability, and product characteristics of SCP infused 48 hrs cohort. Acute GVHD was 50% and 56.5%, and death from any cause was 39.9% versus 39.1%, in the 48 hrs was associated with no adverse outcomes post-HCT, compared to published parameters. In comparison, cryopreserved products during COVID-19 pandemic showed a delayed time to engraftment. While more definitive randomized studies are necessary, our preliminary results suggest that holding products for >48 hrs may be an acceptable alternative to cryopreservation in times of possible transit delay. [Table presented]
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
